Complex study requirements and a lack of validated biomarkers in pain research often result in logistical challenges. At Worldwide, we offer breakthrough solutions to help ensure studies in this challenging indication run seamlessly.
Worldwide is a leader in best practice development for pain research. Our physicians and scientists understand the specific therapeutic and methodological challenges in analgesic research, which allows us to craft tailored study designs and protect trial outcomes. Paired with top-notch operational expertise, our experts ensure rigorous attention to detail, taking into consideration every factor for big-picture solutions to help optimize your pain study.
Vice President, Neuroscience, Scientific Solutions
Christine Moore, PhD, is an experimental psychologist by training with expertise in clinical trial methodology, particularly in analgesia. With 25+ years of drug development experience, her expertise extends from operations to commercialization across breakthrough cancer pain, osteoarthritis, chronic low back pain, acute pain models, neuropathic pain, and migraines.
We’re at the forefront of placebo response mitigation, offering several years of experience incorporating this into our pain study designs and statistical analysis plans for meaningful data outcomes.
Our industry-leading approach to CATS provides your study with a team dedicated to delivering rater training, developing novel scales, and simplifying electronic data capture to guarantee data integrity.
Worldwide offers access to top pain and statistics specialists to ensure your outcome measures meet clinical and regulatory guidelines, facilitate patient and site compliance, and have strong medical oversight required for successful trial execution.
Worldwide brings extensive experience across pain and addiction research, enabling us to provide the right blend of tried-and-true logistics, innovative study designs, and thoughtful outcome measures to augment objectivity in this nebulous field of research.
Worldwide was founded to help improve research for neurology patients. Decades later, we’ve done it all, working on a staggering number of compounds and indications in every phase. Now, Worldwide is one of the few full-service CROs that provides integrated rater training, scale management, bespoke assessment development, and a broad range of other highly specialized consulting services, in addition to our top-notch global network of study execution experts.
Our Cognitive Task Force and scale development work speak volumes about our commitment to Alzheimer’s and dementia research. At Worldwide, we design and execute rigorous, compassionate studies we’d be happy to have our own family and friends take part in, carefully protecting the patient experience and maintaining compelling data integrity to get products to market even in this competitive research space.
Rare neurological diseases each have unique hurdles for developing compelling outcomes assessments that can demonstrate efficacy with small patient populations. Worldwide is a leader in rare disease recruitment, novel endpoint development, and innovative study designs. We deliver specialty studies that apply our overarching knowledge in neurological conditions and rare diseases to thoughtful study designs, respecting patient communities and generating the data sponsors need to advance their compound to market.
A crowded research space makes it difficult to weed the subjectivity out of the science—which demands a CRO with psychiatry know-how from the ground up and the top down. Our proven track record for patient recruitment and engaged investigator networks speaks volumes about our expertise in psychiatric trial development and execution.
We’ve been a part of industry-sponsored psychedelic trials since they began. Our Psychedelic Center of Excellence has a comprehensive approach to the complex operational delivery of these trials and working with patients and sites for study success.